Becton Dickinson & Co.
BDX
Market Cap$68.66B
Close$
Earnings Call Q1 2024
February 1, 2024 - AI Summary
BD reported Q1 revenue of $4.7 billion, with organic growth of 2.4%, driven by strong performance in the Interventional segment and solid growth in the Medical segment.
The company raised its FY '24 guidance, increasing the midpoint of its organic revenue growth range to slightly above 5.8% and raising its adjusted diluted EPS guidance to a range of $12.82 to $13.06.
BD's Alaris Infusion System is progressing well, and the company now expects it to contribute at least $200 million in revenue for fiscal '24.
Exclusive for Stockcircle Pro members
Sign up
$329.57
40.9% upside
Current Fair Value
40.9% upsideUndervalued by 40.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $68.66 Billion |
|---|---|
| Enterprise Value | $83.59 Billion |
| Dividend Yield | $3.6984 (1.59%) |
| Earnings per Share | $4.2 |
| Beta | 0.57 |
| Outstanding Shares | 288,902,000 |
| Avg 30 Day Volume | 1,154,610 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 55.26 |
|---|---|
| PEG | -131.0 |
| Price to Sales | 3.49 |
| Price to Book Ratio | 2.69 |
| Enterprise Value to Revenue | 4.29 |
| Enterprise Value to EBIT | 40.21 |
| Enterprise Value to Net Income | 68 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
ESG Score
No data
About Becton, Dickinson And Co.
72,000 employees
CEO: Thomas Polen BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of hea...